BioMedBridges : The BMS Cluster Project

1. BioMedBridges: The BMS Cluster Project Providing research and data links between the ESFRI BMS RI Hinxton March 2012 Janet Thornton Director, EMBL-EBI

2. BioMedBridges • First European consortium coordinated by ELIXIR • FP7 Call 8 2.3.2: Award €10.6M, 4 years, 21 organisations, 12 WP • To “build bridges” between the ESFRI BMS Research Infrastructures • Participants are ESFRI BMS RI & European e-Infrastructures • Deliverables are infrastructure components that will provide computational ‘data and service’ bridges between the ESFRI BMS RI, clustering them together and linking basic biological research data to data in the other domains. • Also includes: GÉANT, DANTE, EGI.eu, PRACE & CERN • Providing secure, robust and ethical access to data for a wide range of users will be the major effort of the project...

3. BioMedBridges: Participating Organisations

4. BioMedBridges Objectives e-infrastructure BioMedBridgeswill construct the e-infrastructure to allow interoperability between data and services in the biological, medical, translational and clinical domains. Data and services It will provide the computational ‘data and service’ bridges between the individual biological and medical sciences (BMS) research infrastructures (RIs), clustering them together and linking the basic biological research and data to the clinical research and associated data.

5. BioMedBridges Work Packages 1-12 WP2 • Management WP1 • Outreach • Standards description and harmonisation WP3 • Technical integration WP4 • Secure access WP5

6. Five Use Cases WP6 – WP12 • WP6- Interoperability of large scale image data sets from different biological scales • WP7 - PhenoBridge: crossing the species bridge between mouse and human • WP8 - Personalised Medicine: Integrating complex data sets to understand disease pathogenesis and improve biomarker and treatment selection • WP9 - From cells to molecules: integrating structural data • WP10 - Integrating disease related data and terminology from samples of different types • Technology watch WP11 • Training WP12

7. The ESFRI BMS RI depend on each other

8. ESFRI BMS RI and Europe 2020 Europe 2020 is the name of the EU strategy for economic growth Demographics, a sustainable food supply and environmental protection have been identified as particular challenges Emerging pandemics and bioterrorism also present threats European industry is facing unprecedented competition from emerging economies ICT and life-sciences research have been identified as providing particular opportunities for growth The ESFRI BMS RI will enable solutions to these challenges

9. BioMedBridges Objectives BioMedBridgeswill construct the e-infrastructure to allow interoperability between data and services in the biological, medical, translational and clinical domains. It will provide the computational ‘data and service’ bridges between the individual biological and medical sciences (BMS) research infrastructures (RIs), clustering them together and linking the basic biological research and data to the clinical research and associated data.

10.  Building bridges that cross different… • spatial scales • from molecules through cells and organs to humans and the environment • species • from bacteria, through model organisms (eg mouse) to man • temporal scales • from nanoseconds of molecular motions, to seconds of a heartbeat, to years of a human life and the aeons of evolution • technologies and the heterogeneous data they generate • from the nanotechnology of sequencing through the spectroscopy of cellular and whole organism imaging to synchrotrons for structure determination • research communities who have no tradition of working together • from basic scientists to clinicians and environmentalists.

11. From Molecules to Medicine…

12. BioMedBridges Management Coordinator – Janet Thornton Supported by a project manager Scientific Advisory Board Ethical Governance Committee Representatives of the medical RIs Executive Steering Committee Representatives of the 10 BMS Infrastructures Technical Coordination Committee Chairs & Co-Chairs of WPs E-Advisory Taskforce External independent ethics advisory Advisory Coordination

13. WP1: Management Objectives • To manage the BioMedBridges project from Year 1-4 • To organise the management meetings for all the project including: • the Annual General Meeting for all partners; • the Executive Steering Committee meetings (twice pa) • the regular meetings of the Technical Working Group (up to 4 times pa) • To organise the Scientific Advisory Committee and their annual meeting, including reporting back to all partners • To provide good communication between all partners, through a professional web site • To ensure timely and appropriate reporting to the commission and completion of deliverables in all Work Packages • To develop metrics to assess the progress of the grant and its impact on the BMS community • To develop with all partners a plan for sustainability of the infrastructure built during the project, following completion of the grant

14. Report from Executive Steering Committee • AGM • Next AGM in March 2013 (ECRIN (Christian Ohmann) to organise in Dusseldorf) • Possible Dates: • Monday, Tuesday, 11-12 March 2013 • Wednesday, Thursday 20-21 March 2013 • Final AGM 2015 Oct-Dec in Brussels? – Organised by EATRIS • ?? Venue needed for 2014 – any offers? • Executive Steering Committee Meeting Plans • Need Nominations - Infrastructure Coordinators or their reps plus nominated deputy • Meeting at AGM (once pa) • Telephone Conferences every 3 months (First Tuesday of the month at 4pm CET; 5pm UK time) • Technical Steering Committee • Telephone Conferences every month • ?? Meeting at AGM – this year as whole group. Next year – how do we want to do this?

15. BioMedBridges Scientific Advisory Board Dr. Lee Harland, Pfizer Ltd, UK Professor Larry Hunter, University of Colorado, USA Professor Bartha Maria Knoppers, McGill University, Canada (tbc) Professor Peter Lichter, German Cancer Research Center, Germany Professor Babis Savakis, University of Crete, Greece Professor Eero Vuorio, University of Turku, Finland

16. BioMedBridges e-Advisory Task Force Neil Geddes (Chair) – STFC, UK – presenting e-Science Dai Davies – representing DANTE & networking Bob Jones – CERN, representing a large institute, with a huge computational infrastructure KimmoKoski – CSC, Finland – representing EUDAT & HPC Steven Newhouse – EGI, NL – Representing the Grid community

17. ETHICS: Requirements from ethics report 1 Where applicable, copies of ethical approvals must be submitted to the EC andreported as a deliverable. Data samples used in this project are either legitimately available commercially or have been obtained following appropriate ethical approval. A data controller dedicated to the project should be designated. An external independent Ethics advisor must be appointed A report by the Ethics Advisor must be submitted to the European commission

18. Requirements from ethics report 2 • Confirm that no additional new data will be collected • Provide information on procedures that will be implemented for data management • Confirmation of compliance with National and EU legislation. • Provide more information on the use case of personalised medicine • Applicants must address the potential for unforeseen usage of and the possibility for ‘mission creep’.

19. Tasks ET1 Provide an ethics management report to each meeting of BioMedBridges Executive Steering Committee ET2 Analyse the requirements from the Ethics Review Report ET3 Review the draft Ethical Governance Framework document ET4 Monitor the compliance of the project beneficiaries with the Ethical Governance Framework ET5 Prepare new versions of the Ethical Governance Framework for approval by the Executive Steering Committee ET6 Support the External Independent Ethics Advisor in the preparation of Progress of Compliance with Ethics Requirements Reports

20. Deliverables ED1 The Ethical Governance Framework for BioMedBridges (Month 18) ED2 Progress of Compliance with Requirements of the Ethics Review Report (Month 36) ED9 External Independent Ethics Advisors Report (Month 48)

21. Proposal from Steering Committee • Establish the Ethical & Legal Governance Committee: • Composition • Chaired by J Thornton (ELIXIR) • Representatives from ECRIN, BBMRI & EATRIS & EMBRC • Two external advisers: • Ethics (Ethics adviser of WTSI) • Legal EU Law adviser (Jan-Eric to provide names) • First Meeting (by teleconference asap) • Agreement from BioMedBridges needed by open vote

22. Task 4: Provision of a professional web site To provide the project with a public face To act as a management tool The internal/restricted part of the web site will be used both as a workplace and as a repository of documents. D1.1 Web Site (Month 12) (EMBL-EBI)

23. Task 5: Reporting on the Project to Commission • The project coordinator will be responsible for reporting to the commission, with help from the project manager. • Reports from each work package will be delivered by the chair of that work package to the project coordinator, who will then combine these reports to deliver a coordinated report. D1.3 Annual Report (Month 12) (EMBL-EBI) D1.4 Annual Report (Month 24) (EMBL-EBI) D1.5 Annual Report (Month 36) (EMBL-EBI) D1.6 Final Report & Sustainability Plan (Month 48) (EMBL-EBI)

24. Task 6: Developing and monitoring progress and impact D1.2 Devise Metrics to measure progress and impact of construction (Month 12) – all partners The management bodies will develop procedures and metrics at the beginning of the grant to measure the progress of the grant and its impact on the biological and medical research communities. These metrics will be reported annually. All the partners involved in this WP will have responsibility for this task.

25. Task 7: Developing Sustainability Plan D1.6 Final Report & Sustainability Plan (Month 48) (EMBL-EBI) The executive steering committee will monitor the sustainability of the infrastructure under construction. All the partners involved in this WP will have responsibility for this task. In the last year of the project the executive steering Committee will report on the long term sustainability of each component delivered.

26. BioMedBridges Work Packages • WP1 Management • WP2 Outreach and inreach • WP3 ESFRI BMS Standards Description and Harmonization • WP4 Technical integration • WP5 Secure access • Five Use Cases WP6 – WP12 • WP6 Interoperability of large scale image data sets from different biological scales • WP7 PhenoBridge - crossing the species bridge between mouse and human • WP8 Personalized Medicine - integrating complex data sets to understand disease pathogenesis and improve biomarker and treatment selection • WP9 From cells to molecules - integrating structural data • WP10 Integrating disease related data and terminology from samples of different types • WP11 Technology Watch • WP12 Training

27. WP3: Standards description & harmonization • It will only be possible to exchange and link data between the different ESFRI BMS domains if they use common identifiers, and harmonised content, syntax and semantics. In order to achieve this, this use case will create: • An ESFRI BMS Online Dictionary of common molecular identifiers • A mapping and registry of ESFRI BMS standards • A report reviewing national sample safety regulations and an XML schema supporting safety assessment • An ESFRI BMS Meta Service Registry • An harmonisation semantic standards

28. WP4: Technical integration • Implement shared standards from WP3 to allow for integration across the BioMedBridges project • Expose the integration via use of REST based Web-Services interfaces optimised for browsing • Expose the integration via use of REST based Web-Services interfaces optimised for programmatic access • Expose appropriate meta-data information via use of Semantic Web Technologies • Pilot the use of semantic web technologies in high-data scale biological environments

29. WP5: Secure access Create a security framework that will address the ethical, legal and regulatory issues resulting from sharing data and providing access to biomaterials in order to ensure that the infrastructure components developed are compliant with national and European regulations, privacy rules and access requirements. • Document the regulationsand the privacy and security requirements including intellectual property rights that must be observed when accessing and sharing data and bio-samples • Create a tool for assessing regulatory and ethical requirements • Define the security architecture and framework, based on security requirements and risks identified • Implement the security framework

30. BioMedBridges: Data protection • Access to much of the data in the ESFRI BMS domains has Ethical, Legal or Societal Implications (ELSI) • It includes Personally Identifiable Information (PII) • Working with these across organisational boundaries • Working with these across national boundaries • Linking these to other data such as scientific data (cf. reidentification, inferential attack)

31. ELSI data in the life-sciences Clinical research Translational research Biological sample management Publishing, attribution and intellectual property Environmental protection Others...

32. ELSI data and the ESFRI BMS & ENV RI • Clinical research • ECRIN, EuroBioImage, EU-OpenScreen, EHRINA, ELIXIR • Translational research • EATRIS, EuroBioImage, EU-OpenScreen, EHRINA, ELIXIR, InfraFrontier • Biological sample management • BBMRI and all the others. • Publishing, attribution and intellectual property • All of them • Environmental protection • LifeWatch, BBMRI, ELIXIR

33. WP6: Use case 1 Title: “Interoperability of large scale image data sets from different biological scales” • The use case will demonstrate the utility of the interoperability of large scale image data sets from different biological scales (cell – tissue – organism) to enable drug target and biomarker discovery for human disease with cancer as an example.

34. WP7: Use case 2 Title: “PhenoBridge – crossing the species bridge between mouse and human” • The mouse is an important model organism for human disease. This use case will harmonise ontological descriptions of phenotype in both mouse and human using diabetes & obesity as examples: • Identify and develop annotations, terminologies, and mappings between terminologies for human and mouse models of diabetes and obesity • Identify and group related interacting parameters in human and mouse which determine complex clinical and molecular phenotypes • Formalise rules for phenotypic annotation in human and mouse to work towards automation of phenotypic discovery • Deploy a service which builds on the rules, terminologies and annotations generated in this use case at the EMBL-EBI

35. WP8: Use case 3 Title: “Personalized Medicine – integrating complex data sets to understand disease pathogenesis and improve biomarker and treatment selection” • Personalized medicine (PM) is starting to have a major impact on the treatment of cancer but there is as yet no systematic effort to make PM data available to scientists and clinicians in an ethical, robust and sustainable manner. This use case will: • Develop a process for sharing & access PM data in a secure and ethical manner • Define types of PM data being generate by the different ESFRI Projects • Develop mechanisms of interoperability for PM data types

36. WP9: Use case 4 Title: “From cells to molecules – integrating structural data” • Modern structural biology is producing data about biological molecules at a far wider range of resolutions that previously. If the value of these data is to be maximised then tools are needed that will allow data at multiple resolutions to be deployed against important biological and medical problems. This use case will develop software, database and web-based services to do this using the components created by the other work packages.

37. WP10: Use case 5 Title: “Integrating disease related data and terminology from samples of different types” • Modern clinical research needs large collections of high-quality well-documented samples from humans and model organisms. This use case will • Mapping between data elements in EMBL-EBI’s BioSample Database and selected resources from BBMRI • A prototype linking ICD10/SNOMED CT concepts to Ensembl gene identifiers • A prototype federated query interface.

38. BioMedBridges WP11: Technology Watch • Comprises representatives of GÉANT, DANTE, EGI.eu, PRACE & CERN as well as technical experts from the ESFRI BMS RIs • Bring together the technical experts of the BioMedBridges partners European ICT & e-Infrastructures to monitor and report on developments and provide advice to the project • Facilitate adoption of e-Infrastructure technologies by the BioMedBridges Work Packages and the ESFRI BMS RI • Communicate advice from the ICT Infrastructures and the e-Infrastructures to the BioMedBridges partners • Will produce annual reports on status of e-Infrastructures relevant to the progress of BioMedBridges including requirements for use cases & recommendations for adoption of new technologies and standards.

39. BioMedBridges started 1 January 2012…

40. Thank you for your attention…